Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 03:00 ET | Source: Cytovation

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society ...
February 13, 2025 03:00 ET | Source: Cytovation

Cytovation Appoints Martin Dewhurst to its Board of Directors

Brings over 30 years of life sciences industry experienceCo-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025 – Cytovation ASA, a clinical stage oncology company...
January 23, 2025 03:00 ET | Source: Cytovation

Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer

Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites...
September 13, 2024 03:00 ET | Source: Cytovation

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of...
December 20, 2023 03:00 ET | Source: Cytovation

Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors

Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today...
October 11, 2023 03:00 ET | Source: Cytovation

Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

Findings confirm unique dual mechanism of action and fast-to-market target indication for potentially registrational trial All CICILIA trial endpoints met, with CyPep-1 demonstrating consistent...
July 05, 2023 03:00 ET | Source: Cytovation

Cytovation appoints Olav Hellebø to its Board of Directors

Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the...
June 02, 2023 03:00 ET | Source: Cytovation

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the...
March 21, 2023 04:00 ET | Source: Cytovation

Cytovation appoints Iman Barilero as Chief Development Officer

Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that...
February 15, 2023 03:00 ET | Source: Cytovation

Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors

Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...